SCHEMBL1955264

SCHEMBL1955264

Cc1ccc(-n2sc(C(=O)c3ccccc3)cc2=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
PMM2 O15305 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
G6PD P11413 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
MPI P34949 1/20 0.43
CASP3 P42574 1/20 0.43
PHOSPHO1 Q8TCT1 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
CES2 O00748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9263852 0.75 PHOSPHO1 (0.47) NPSR1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL28550660 0.72 KAT2B (0.46) NPSR1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL12632651 0.69 KAT2B (0.61) NPSR1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL259065 0.69 ALDH1A1 (0.80) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL10877169 0.69 ALDH1A1 (0.80) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL235 0.69 ALDH1A1 (0.80) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
Benzophenone SCHEMBL5162782 0.69 ALDH1A1 (0.80) NPC1RAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL9262493 0.69 MAPT (0.46) NPSR1NPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL15030108 0.68 ALDH1A1 (0.70) NPC1RAB9AALDH1A1SMN1; SMN2HPGD
Bicarbonate SCHEMBL9817083 0.67 ALDH1A1 (0.76) NPC1RAB9AALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518957-B2 Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-08-27 US disclosed
US-20120264769-A1 METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF The United States of Americia, as represented by the Secretary, Department of Health and Human Serv (US) 2012-10-18 US disclosed
EP-2507241-A1 METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2012-10-10 EP disclosed
WO-2011068978-A1 METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264769-A1 METHANOCARBA ADENOSINE DERIVATIVES AND DENDRIMER CONJUGATES THEREOF ADORA3, ADORA2A, ADORA1 NPSR1 766/4885NPC1 1722/4885RAB9A 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.